^
Association details:
| Biomarker: | ER D538G |
|---|---|
| Cancer: | Estrogen Receptor Positive Breast Cancer |
| Drug: | eltanexor (KPT-8602) (XPO1 inhibitor, Nuclear export inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Therapeutic Potential of Combining Eltanexor with Tamoxifen to Treat Primary and Metastatic Estrogen Receptor Positive (ER+) Breast Cancers
Published date:
12/02/2023
Excerpt:
Our results show that mice harboring MCF7-ESR1Y537Sxenograft tumors had significantly less (P < .05) flank tumor growth when administered a treatment regimen of TAM and eltanexor compared to control mice. In metastatic tumor models, we observed decreased metastatic burden in mice harboring MCF7-ESR1 D538G and MCF7-ESR1Y537S tumors when coadministered TAM and eltanexor.
Secondary therapy:
tamoxifen
